Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

2025-05-09 08:50:38 ET

Pharming Group N.V. (PHAR)

Q1 2025 Earnings Conference Call

May 08, 2025, 07:30 AM ET

Company Participants

Fabrice Chouraqui – CEO

Stephen Toor – CCO

Anurag Relan - Chief Medical Officer

Jeroen Wakkerman - CFO

Conference Call Participants

Jeff Jones – Oppenheimer

Joe Pantginis - H.C. Wainwright

Alistair Campbell - RBC Capital Markets

Simon Scholes - First Berlin

Presentation

Fabrice Chouraqui

Hello, everyone, and welcome to the Q1 2025 Call. I'm Fabrice Chouraqui, CEO of Pharming, and I'll be joined on this call today by Stephen Toor, our Chief Commercial Officer, Anurag Relan, our Chief Medical Officer, and Jeroen Wakkerman, our Chief Financial Officer.

We'll be making forward-looking statements in this call that are based upon our current insights and plans. As you very well know, this may differ from future results.

First of all, let me say that I had a great first three months at Pharming. I mean, the passion and the commitment of all employees to serving rare disease patients is really palpable throughout the company, whether you are at the production facilities, at the headquarter or with the field. And this mindset of going this extra mile is clearly part of the DNA of the company and not just a few words on a culture slide as I've seen it actually too often.

So everyone is clearly determined to realize the vision that we've set for the company, which is to make Pharming a leading global rare disease company with a diverse portfolio and presence in large markets that leverages a proven and efficient clinical development, supply chain and commercial infrastructure.

Our results in the first quarter of 2025 are a good illustration of the solid growth foundation that we have built to realize this vision. We've had a strong start of the year with our total revenues increasing by 42% in the first quarter and a significant improvement of our bottom line, which supported an upgrade of our full year guidance....

Read the full article on Seeking Alpha

For further details see: